Research Data · Updated May 2026
Peptide Research Statistics 2026
We track 2,147 scientific publications across 14 bioactive peptides. This page is updated monthly. Researchers, journalists, and clinicians: cite freely.
2,147+
Publications Analyzed
14
Peptides Tracked
30
Active Clinical Trials
2026
Years Analyzed
Publications Per Year — All Peptides Combined
Total PubMed-indexed publications across all 14 tracked peptides.
2015 62
2016 73
2017 76
2018 57
2019 73
2020 81
2021 115
2022 79
2023 111
2024 130
2025 181
2026 139
Most Researched Peptides
Ranked by total PubMed publications. Click any peptide for our in-depth research guide.
| # | Peptide | Publications | 2025→2026 Growth | Active Trials |
|---|---|---|---|---|
| 1 | TB-500 | 606 | -61.1% | 1 |
| 2 | MOTS-c | 266 | -34.7% | 5 |
| 3 | BPC-157 | 205 | -18.8% | 1 |
| 4 | Semax | 204 | -62.5% | — |
| 5 | KPV | 146 | -20% | — |
| 6 | Retatrutide | 142 | -48.3% | 16 |
| 7 | Epitalon | 138 | -60% | — |
| 8 | Selank | 125 | -16.7% | — |
| 9 | Tesamorelin | 100 | +150% | 3 |
| 10 | GHK-Cu | 73 | +37.5% | 1 |
| 11 | Sermorelin | 52 | +300% | 3 |
| 12 | Ipamorelin | 48 | — | — |
| 13 | CJC-1295 | 31 | +700% | — |
| 14 | AOD-9604 | 11 | — | — |
Fastest Growing Research Areas
Peptides with the highest publication growth from 2025 to 2026.
Active Clinical Trials by Peptide
Data from ClinicalTrials.gov. Includes recruiting, active, and not-yet-recruiting studies.
| Peptide | Total | Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|---|---|
| Retatrutide | 16 | — | — | — | — |
| MOTS-c | 5 | — | — | — | — |
| Sermorelin | 3 | — | — | — | — |
| Tesamorelin | 3 | — | — | — | — |
| BPC-157 | 1 | — | — | — | — |
| TB-500 | 1 | — | — | — | — |
| GHK-Cu | 1 | — | — | — | — |